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1. Introduction
DNA repair is critical for maintaining genomic integrity. The DNA damage such as those
induced by endogenous processes (methylation, hydroxylation, oxidation by free radicals) or
by exogenous agents such as ionizing radiation, environmental toxins, and chemotherapy is
processed through the DNA repair machinery in cells. At least six distinct DNA repair
pathways have been described. A detailed discussion of individual pathways is beyond the
scope of this chapter as several recent excellent reviews on DNA repair are available [1-6].
Briefly, direct repair is involved in the repair of alkylated bases (such as O6 methyl guanine)
by MGMT (O6 methyl guanine DNA methyl transferases [7-10]. DNA mismatch repair (MMR)
corrects base-base mismatches and insertion-deletion loops (IDLs) erroneously generated
during DNA replication and by exogenous DNA damage [11-13]. Bulky DNA adducts are
processed through the nucleotide excision repair pathway (NER) [14-16]. DNA double strand
breaks are repaired through the homologous recombination pathway (predominantly during
S-phase of cell cycle) [17-19] or the non-homologous end joining pathway (NHEJ), that operates
outside the S-phase of the cell cycle [20-22]. DNA base damage is processed by the base excision
repair (BER) machinery. In the current chapter we focus on BER. Evolving preclinical and
clinical data suggests that BER factors are likely to be important prognostic, predictive and
therapeutic targets in cancer.
2. Base excision repair pathway (BER)
Exogenous as well as endogenously derived reactive metabolites cause DNA damage such as
base oxidation, deamination and alkylation. If the damaged bases are left unrepaired, then dur‐
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ing replication or transcription misincorporation of erroneous complementary bases usher mu‐
tagenesis. For example, reactive oxygen species (ROS) generated during cellular respiration,
phagocytosis, inflammation and in tumour hypoxia milieu can lead to base oxidation and gen‐
eration of oxidised bases such as 8-hydroxyguanine (8-oxoG) [23]. DNA polymerase inserts ad‐
enine opposite to 8-oxoG, resulting in GC to AT transversion mutations after replication.
Similarly, pyrimidine oxidation leads to the formation of 5-hydroxycytosine (5-OHC) which
leads to the insertion of a thymine creating a potential mutagenic lesion [24]. Purine deamina‐
tion products such as hypoxanthine and xanthine generated from adenine and guanine respec‐
tively are highly mutagenic. Hypoxanthine in DNA can cause AT to GC mutations, whereas
xanthine generate GC to AT mutations [25]. Deamination of cytosine generates uracil which can
occur in DNA at a frequency of upto 100–500 per cell per day. Uracil misincorporation can in‐
duce CG to TA transition mutations [26]. Although endogenous S-adenosyl methionine (SAM)
participates in targeted enzymatic DNA base methylation, non-enzymatic methylation of ring
nitrogen of purine base adenine can be cytotoxic[26]. Exogeneous agents that cause base alkyla‐
tion are common chemotherapeutic agents and include mono functional alkylating agents [27]
(e.g.  temozolomide,  nitrosurea  compounds,  alkylsulfonates)  and  bifunctional  alkylating
agents (e.g. cisplatin, mitomycin C, nitrogen mustards). DNA bases damaged by oxidation, de‐
amination and alkylation produce a non-helix distorting, non-bulky base lesion. Such lesions
are the prime repair target of BER [6, 28-30].
BER is a complex process and utilizes a number of enzymes and accessory scaffold proteins (Fig‐
ure 1). DNA glycosylases, AP endonuclease (APE-1) also called REF-1(Redox Effector Factor-1),
DNA Polymerases, flap endonuclease (FEN-1), poly (ADP-ribose) polymerase 1(PARP-1) and
DNA ligases are the key enzymes involved in BER. The core enzymes depend on accessory pro‐
teins such as X-ray cross complementation group 1 protein (XRCC1), proliferating cell nuclear
antigen (PCNA), and protein 9-1-1 for coordinated action. DNA glycosylases initiate BER by ex‐
cising the damaged base from DNA and generating an abasic site. APE1 hydrolyzes the phos‐
phate bond 5’ to the AP site leaving a 3’-OH group and a 5’-dRP flanking the nucleotide gap.
Polymerase β (pol β) excises the 5’-dRP moiety generating a 5’-P. Members of the poly (ADP-ri‐
bose) polymerase (PARP) family of proteins get activated by single strand DNA breaks induced
by APE1 and catalyze the addition of poly (ADP-ribose) polymers to target proteins, affecting
protein-protein interactions. PARP may also be involved in the coordination of BER. At this
point, BER can proceed through the short-patch (SP-BER) where pol β introduces a single nu‐
cleotide with the help of XRCC1. Ligase-IIIα subsequently seals the DNA nick establishing the
phosphodiester DNA backbone. The long patch (LP-BER) processes those lesions that cannot be
handled by the short patch such as oxidised AP sites. PCNA mediated Polymerase δ/ε introdu‐
ces two to eight nucleotides past the abasic site. The resulting overhang DNA is excised by FEN1
endonuclease and the nick is then sealed by DNA ligase I.[28-32]
2.1. BER factors are promising biomarkers in cancer
Prognostic factors are defined as patient and/or cancer characteristics that help to estimate
patient survival independent of treatment. Conventionally these include patient age, fitness
to withstand treatment toxicity (usually measured as performance status), tumour stage,
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histological grade, neuro-lymphovascular invasion by cancer cells, presence or absence of
certain signal protein expression (for example Her-2 in breast cancer is a poor prognostic
marker). Predictive factors are those factors that help estimate the probability of a patient
responding to a specific treatment. For example BRAF V 600 gene mutation in patients with
metastatic melanoma predicts the response to treatment with Vemurafenib [33].
Figure 1. DNA glycosylase initiates BER by excising the damaged base from DNA and generating an abasic site. APE 1
nicks the phosphodiester bond and hydrolyzes the phosphate bond 5’ to the AP site leaving a 3’-OH group and a 5’-
dRP flanking the nucleotide gap. Pol β excises the 5’-dRP moiety generating a 5’-P. The short-patch (SP-BER) where pol
β introduces a single nucleotide with the help of XRCC1. Ligase-IIIα subsequently seals the DNA nick establishing the
phosphodiester DNA backbone. The long patch (LP-BER) processes those lesions that cannot be handled by the short
patch such as oxidised AP sites. PCNA mediated Polymerase δ/ε introduces two to eight nucleotides past the abasic
site. The resulting overhang DNA is excised by FEN1 endonuclease and the nick is then sealed by DNA ligase I.
Chemotherapeutic agents and ionizing radiation achieve cellular cytotoxicity by inducing
DNA base damages [34]. However proficient BER in cancer cells results in therapeutic resist‐
ance and adversely impact patient outcomes. BER factors, therefore, are emerging as important
prognostic factors as well as predictors of response to cytotoxic therapy in patients. For exam‐
ple, Temozolomide is an effective treatment for patients with high grade brain tumours. It indu‐
ces O6-meG, N3-meA and N7-meG base alkylation lesions which are processed by BER. [35].
Similarly, Melphalan which is used in the treatment of multiple myeloma induces N3-meA le‐
sions that is processed through BER [36]. Thiotepa is used with or without total body irradiation
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as a conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell
transplantation in haematological diseases in adult and paediatric patients. Thiotepa produces
formamidopyrimidine, 7-Methyl-formamidopyrimidine base lesions [37] which is repaired by
BER. Dacarbazine is used in the treatment of patients with advanced malignant melanoma and
Procarbazine is used in the treatment of Hodgkin's disease. They both produce O6-meG, N7-
meG alkylation lesions which are targets of BER [38]. Streptozotocin generates O6-meG, N3-
meA, N7-meG metabolites and is used in the treatment of neuroendocrine tumours of the
gastro-intestinal (GI) tract.[39]. Platinating agents usually cause DNA inter-strand lesions
which are repaired via NER, MMR and HR pathways (see table 1). Cisplatin is used in the treat‐
ment of advanced and metastatic non-small cell lung cancer (NSCLC), small cell carcinoma
(SCLC), head and neck squamous cell carcinoma (HNSCC), germ cell tumour (GCT), gastric,
pancreatic, bladder and cervical cancer. In addition to the DNA inter-strand lesions it also gen‐
erates reactive oxygen species (ROS) that results in oxidative base damages. ROS derived base
damages are also seen in patients with colorectal cancer (CRC) treated with Oxaliplatin. ROS in‐
duced base damages are also seen with anthracyclines (epirubicin and doxorubicin), used in the
treatment of breast, gastric, ovarian, sarcoma and in haematological malignancy. The antimeta‐
bolite gemcitabine used in the treatment of NSCLC, pancreatico-biliary, bladder, breast and
ovarian cancer also causes DNA base damage. Given the essential role of BER in cytotoxic thera‐
py induced base damage, it is perhaps not surprising to note that several components of BER are
promising prognostic and predictive factors. The following section will review individual
markers and their relevance to cancer therapy.
2.2 APE1
Human apurinic / apyrimidinic endonuclease 1 (APE1) is a major endonuclease accounting
for > 95% of the cellular AP endonuclease activity in most of the human cell lines [40]. It is also
involved in redox regulation of transcription factors [41-43]. APE1 may be expressed in the
cytoplasm and/ or in the nucleus of cancer cells. Although the precise sub-cellular localization
and regulation is not clearly known, altered localization may have prognostic or predictive
significance in patients. Table 2 summarizes the current knowledge regarding the association
between APE1 and its role as a biomarker. We recently demonstrated that APE1 is over
expressed in Ovarian, Gastro-oesophageal and pancreatico-biliary cancers [44]. In ovarian
cancers, nuclear APE1 expression was seen in 71.9% of tumours and correlated with tumour
type (P 0.006), optimal debulking (P 0.009), and overall survival (P 0.05). In gastro-oesophageal
cancers previously exposed to neoadjuvant chemotherapy, 34.8% of tumours were positive in
the nucleus and this correlated with shorter overall survival (P 0.005), whereas cytoplasmic
localisation correlated with tumour de-differentiation (P 0.034). In pancreatico-biliary cancer,
nuclear staining was seen in 44% of tumours. Absence of cytoplasmic staining was associated
with perineural invasion (P 0.007), vascular invasion (P 0.05), and poorly differentiated
tumours (P 0.068). [45]. In another study, a cohort of ninety one NSCLC patients treated with
radical resection, tumour samples were analyzed for expression of APE1 protein. In patients
with adenocarcinoma, cytoplasmic expression of APE1 was significantly associated with poor
survival rate in univariate (P 0.01) and multivariate (P 0.07) analyses. In addition, a cytoplasmic
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expression was also predictive of worse prognosis (log-rank test, P 0.02) in NSCLC patients
with lymph node involvement, regardless of the histology [46]. In another study, high nuclear
and cytoplasmic APE1 expression was demonstrated in prostate cancer biopsy samples [47].
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Abbreviations: BER : base excision repair pathway, NER: Nucleotide excision repair pathway, MMR: mis match repair
pathway, HR: homologous repair pathway, NHEJ: non homologous end joining repair pathway.
Table 1. Cytotoxic agents and DNA Repair pathways
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BER factor Key findings Year of
publication
Ref
1 APE1 Profound deregulation of APE1 acetylation status in triple
negative breast cancer
2012 [52]
2 APE1 Ape1 expression elevated by p53 aberration may be used to




APE1 genetic variants may be associated with endometrial
cancer in Turkish women.
2012 [54]
4 APE1 APE1 T1349G polymorphism may be a marker for the
development of gastric cancer in the Chinese population
2012 [55]
5 APE1, XRCC1 APE1 allele and the 399Gln XRCC1 allele apparently increased
the risk of colon cancer
2012 [57]
6 APE1 APE1-656 T "/> G polymorphism has a possible protective effect




Polymorphisms within BER genes may contribute to the
tumorigenesis of lung cancer.
2011 [59]
8 APE1 Loss of APE1 expression causes cell growth arrest, mitochondrial
impairment and apoptosis
2011 [107]
9 APE1 Genetic variant rs1760944 in APE1 was associated with gastric




APE1 Asp148Glu and hOGG1 Ser326Cys polymorphisms might
be associated with increasing risk of CRC in a Turkish population.
2011 [58]
11 APE1 Polymorphisms of APE1 may confer susceptibility to RCC. 2011 [60]
12 APE1 Cytoplasmic localization of APE1 is associated with tumor
progression and might be a valuable prognostic marker for EOC
2011 [51]
13 APE1 Genetic variant in the APE1 promoter may modulate risk of
glioblastoma.
2011 [61]
14 APE1 Changes in the expression of APE1 might contribute to lip
carcinogenesis.
2011 [108]
15 APE1 APE1 inhibitors potentiated the cytotoxicity of alkylating agents
in melanoma and glioma cell lines
2011 [109]
16 APE1 Ape1 promotes radiation resistance in pediatric ependymomas 2011 [110]
17 APE1 The APE1 expression had significant correlation with
osteosarcoma local recurrence and/or metastasis.
2010 [111]
18 APE1 APE1 may be a potential therapeutic target of MM. 2010 [112]
19 APE1 APE1 is a potential drug target in ovarian, gastro-oesophageal,
and pancreatico-biliary cancers.
2010 [44]
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BER factor Key findings Year of
publication
Ref
20 APE1 Nuclear expression of APE1 in gastro-oesophageal cancer
patients treated with neo-adjuvant chemotherapy is associated
with poor prognosis.
2010 [45]
21 APE1 Polymorphism in APE1 gene may affect response to palliative
chemotherapy in NSCLC.
2009 [113]
22 APE1 Altered APE1 expression found in platinum resistant ovarian
cancer patients
2009 [114]
23 APE1 APE1 is up-regulated in the NSCLC 2008 [115]
24 APE1 APE1 activity promotes resistance to radiation plus
chemotherapy in Medulloblastomas and primitive
neuroectodermaltumours
2005 [116]
25 APE1, XRCC1 High APE1 and XRCC1 protein expression levels predict better
cancer-specific survival following radical radiotherapy in bladder
cancer.
2005 [77]
26 APE1 APE1 over expression corresponds to poor prognosis in
osteosarcoma
2004 [117]
27 APE1 APE 1 activity mediates resistance to alkylating agents and
radiation and may be a useful predictor of progression after
adjuvant therapy in a subset of gliomas.
2004 [118]
28 APE1 Cytoplasmic localization of APE1 seems to confer a poor survival
outcome in patients with lung adenocarcinoma. Cytoplasmic
expression of APE1 is a poor prognostic marker in node positive
NSCLC regardless of the Histology.
2002 [46]
29 APE1 Increased expression of APE1 is seen in GCT and may be
responsible for resistance to treatment with chemotherapy and
IR
2001 [119]
30 APE1 APE1 nuclear expression in HNSCC is directly related to
resistance to chemoradiotherapy and poor survival
2001 [120]
31 APE1 Increased APE1 cytoplasmic staining in prostate carcinoma as
compared to BPH
2001 [47]
32 APE1 APE1 expression in carcinompa of the cervix is a marker of radio-
resistance
1998 [121]
Abbreviations: NSCLC: non small cell lung cancer, CRC: colorectal cancer, RCC: renal cell carcinoma, EOC: epithelial ovarian
carcinoma, GCT: germ cell tumour, HNSCC: Head and neck Squamous cell carcinoma, BPH: benign prostatic hypertrophy.
Table 2. APE1
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The  commonly  reported  APE1  polymorphisms  include  Asp148Glu,  Leu104Arg,
Glu126Asp,  Arg237Ala,  Asp283Gly,  Gln51His,  Ile64Val,  Gly306Glu  and  Thr141Gly
[48-50].  In  a  cohort  of  epithelial  ovarian  cancer  patients,  cytoplasmic  APE1  positivity
was  significantly  associated  with  higher  grade  of  tumour  (P  =  0.002),  advanced  stage
(III  +  IV)  compared  to  early  stage  (I  +  II)  patients  (40.7%  vs.  11.8%;  P  =  0.002)  and  a
lower  survival  rate  compared  to  patients  with  cytoplasmic  negative  localization  (P  <
0.05)  of  APE1 [51].  Profound deregulation  of  APE1 acetylation  status  in  triple  negative
breast  cancer  patients  has  recently  been  demonstrated.  This  may  be  a  potential  bio‐
marker  for  breast  cancer  aggressiveness  [52].  In  another  study,  one hundred and twen‐
ty  five  lung  tumour  samples  were  analysed  for  APE1  protein  and  mRNA  expression
by  immunohistochemistry  and  real-time  RT-PCR  respectively.  Cytoplasmic  APE1  over‐
expression  and  p53  aberration  was  shown  to  be  a  potential  predictor  of  poor  survival
and  relapse  in  patients  with  NSCLC[53].  In  a  case  control  study  of  one  hundred  and
four  endometrial  cancer  patients  with  aged matched normal  controls,  APE1 Asp148Glu
genotypes  were  determined  by  PCR-RFLP  assays.  Frequencies  of  Glu+  and  Asp/Glu
genotypes  of  APE1  were  found  to  be  more  prevalent  in  patients  than  controls.  This
may represent  a  future  diagnostic  biomarker  in  endometrial  cancer  [54].  In  a  study in‐
volving  three  hundred  and  thirty  eight  newly  diagnosed  gastric  cancer  patients  and
matched  control,  APE1  genotype  T1349G  polymorphism  was  assessed.  Compared  with
the  APE1  TT  genotype,  individuals  with  the  variant  TG/GG  genotypes  had  a  signifi‐
cantly  increased risk  of  gastric  cancer  (OR 1.69,  95% CI  1.19-2.40).  Further  analyses  re‐
vealed  that  the  variant  genotypes  were  associated  with  an  increased  risk  for  diffuse-
type,  low depth  of  tumour  infiltration  (T1  and T2),  and  lymph node  metastatic  gastric
cancer.  The  APE1  T1349G  polymorphism  may  be  a  biomarker  for  the  development  of
aggressive  gastric  cancer  [55].  Another  cohort  of  nine  hundred  and  twenty  five  gastric
cancer  patients  was evaluated for  the  genetic  variant  rs1760944 in  APE1.  Survival  anal‐
yses  showed a  statistically  significant  (P  0.025,  log-rank test)  differences  in  median sur‐
vival  time between gastric  cancer  patients  with  APE1 rs1760944  TT (55  months)  versus
those  with  GT/GG  (78  months).  These  studies  suggest  that  APE1  polymorphism  is  a
potential  biomarker  in  patients  with  Gastric  cancer  [56].  In  another  study,  significant
differences  in  the  distribution  of  APE1 genotype  were  found between colon  cancer  pa‐
tients  and  healthy  individuals.  The  148Asp  APE1  allele  apparently  increased  the  risk
of  colon cancer  (OR 1.9-2.3),  suggesting it  to  be a  biomarker  in  colorectal  cancer  (CRC)
[57].  Polymorphisms  of  APE1  Asp148Glu  (rs3136820)  were  determined  by  polymerase
chain  reaction  (PCR)  and restriction  fragment  length  polymorphism (RFLP)  methods  in
blood  samples  of  seventy  nine  CRC  patients  at  their  initial  staging  and  two  hundred
and  forty  seven  healthy  controls.  Frequency  of  Glu  allele  of  APE1  Asp148Glu  was
higher  in  CRC  patients  than  in  controls  (P  0.006,  OR  3.43;  95%  CI  1.76-6.70)[58].  In  a
hospital-based  case-control  study  of  four  hundred  and  fifty  five  lung  cancer  patients
and  four  hundred  and  forty  three  controls,  the  single  nucleotide  polymorphisms
(SNPs)  of  APE1  (Asp148Glu  and  -141T/G)  were  genotyped  and  analyzed.  In  a  multi‐
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variate  logistic  regression  model,  individuals  homozygous  for  the  variants  APE1
-141GG showed a  protective  effect  for  lung  cancer  (OR 0.62;  95% CI  0.42-0.91;  p  0.02).
This  study  indirectly  suggests  that  polymorphism  in  APE1  genes  may  be  a  biomarker
and  contribute  in  the  pathogenesis  of  lung  cancer  [59].  In  a  case-control  study  of  six
hundred  and  twelve  renal  cell  carcinoma  (RCC)  patients  and  six  hundred  and  thirty
two  age  and  sex  matched  healthy  controls,  APE1  polymorphisms  (-656  T>G,  rs1760944
and  1349  T>G,  rs1130409)  were  assessed.  Compared  with  1349  TT/TG  genotypes,  the
variant  genotype 1349 GG had a  significantly  increased risk  of  RCC (adjusted odds ra‐
tio  1.47;  95%  CI  1.10-1.95),  suggesting  a  role  for  APE1  polymorphism  as  a  biomarker
in  RCC  [60].  In  a  case-control  study  of  seven  hundred  and  sixty  six  glioma  patients
and  eight  hundred  and  twenty  four  cancer-free  controls  APE1/Ref-1  promoter  -141T/G
variant  (rs1760944)  was  evaluated.  Allele  G  was  associated  with  significant  decreased
glioblastoma risk (OR 0.80;  95% CI 0.65-0.98;  P 0.032)  [61].In  conclusion emerging stud‐
ies  of  APE1  in  tumours  suggest  that  APE1  is  a  promising  biomarker  in  cancer.  How‐
ever,  large prospective studies  are required to confirm these observations.
2.3. XRCC1
X-ray repair  cross-complementing group 1 (XRCC1) is  a  scaffolding protein and coordi‐
nates  BER  [62].  Cells  deficient  in  XRCC1  are  hypersensitive  to  DNA  damaging  agents
such  as  ionizing  radiation  and  alkylating  agents.  Pre-clinically  XRCC1  deficiency  can
induce mutagenesis  [63].  Embryonic  knock out  of  XRCC1 is  lethal.  The most  extensive‐
ly  studied  polymorphisms  of  XRCC1  are  Arg194Trp,  Arg280His,  Arg399Gln,
Arg399Gln,  Pro161Leu  and  Tyr576S.  Ensembl  data  base  records  ten  somatic  mutations
and  six  genetic  variations  of  human  XRCC1gene.  Table  3  summarizes  the  current
knowledge  regarding  the  association  between  APE1  and  its  role  as  a  biomarker.
XRCC1 SNPs  rs1799782  and  rs25487  were  investigated  using  the  TaqMan assay  in  one
hundred  and  eighty  five  pancreatic  cancer  cases  and  one  thousand  four  hundred  and
sixty  five  controls.  The minor  allele,  rs25487 was significantly  associated with pancreat‐
ic  cancer  risk  in  the  per-allele  model  (OR 1.29;  CI  1.01-1.65;  P  0.043).  Haplotype analy‐
sis  of  XRCC1  also  showed  a  statistically  significant  association  with  pancreatic  cancer
risk  [64].  Endometrial  biopsy  samples  in  a  case  control  study  assessed  the  polymor‐
phisms Arg399Gln.  Gln/Gln genotype of  XRCC1was more  prevalent  in  patients  than in
controls  suggesting  XRCC1  polymorphisms  as  a  biomarker  in  endometrial  cancer  [54].
In  a  case  control  study,  polymorphisms  of  XRCC1  Arg399Gln  allele  increased  the  risk
of  colon  cancer  (OR  1.5-2.1)[57].  In  a  cohort  of  ninety  nine  advanced  colorectal  cancer
patients  treated  with  oxaliplatin  based  chemotherapy,  polymorphisms  of  XRCC1
Arg399Gln  (G-->A)  genotypes  were  detected  by  TaqMan-MGB  probe  allelic  discrimina‐
tion  method.  Cox  proportional  hazards  model,  adjusted  for  stage,  performance  status,
and  chemotherapy  regimen,  showed  that  XRCC1  G/G  genotype  increased  the  OR  sig‐
nificantly  (OR 3.555;  95  % CI,  2.119  -  5.963;  P  <  0.01).  The  result  suggests  that  XRCC1
Arg399Gln  polymorphism  is  associated  with  response  to  chemotherapy  and  time  to
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progression  in  advanced  colorectal  cancer  patients.  This  study  pointed  XRCC1  poly‐
morphism as  a  predictive  biomarker  in  advanced CRC patients  treated with oxaliplatin
based chemotherapy [65].
BER factor Key findings Year of
publication
Ref
1 XRCC1 XRCC1 polymorphisms affect pancreatic cancer risk
in Japanese.
2012 [64]
2 XRCC1 Elevated cancer risk associated with XRCC1
polymorphism.
2012 [66]
3 XRCC1 XRCC1 polymorphism might influence the risk of
developing glioma
2012 [68]
4 XRCC1, XRCC3 Polymorphisms in DNA repair genes have roles in
the susceptibility and survival of ovarian cancer
patients.
2012 [69]
5 XRCC1 XRCC1 polymorphism is associated with
significantly increased risk of gastric cancer
2012 [70]
6 XRCC1 High XRCC1 and low ATM were independently
associated with poor survival in gastric cancer
2012 [76]
7 XRCC1 XRCC1 polymorphisms affect pancreatic cancer risk
in Japanese.
2012 [64]
8 XRCC1 Genetic variations in XRCC1 exhibit variation in the
sensitivity to platinum based chemotherapy in
NSCLC
2012 [71]
9 XRCC1 Polymorphisms of XRCC1 gene might have
contributed to individual susceptibility to lung
cancer.
2012 [72]
10 XRCC1 Arg194Trp polymorphism could be associated with
nonmelanoma skincancer and extramammary




11 XRCC1 Polymorphism of XRCC1 Arg399Gln may be a
candidate for contributing to the difference in the
OS of gemcitabine/platinum-treated advanced
NSCLC patients.
2012 [73]
12 XRCC1 XRCC1 Arg399Gln polymorphisms is associated
with a response to oxaliplantin-based
chemotherapy and time to progression in advanced
colorectal cancer in Chinese population.
2012 [65]
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BER factor Key findings Year of
publication
Ref
13 XRCC1 The 751 Lys/Gln polymorphism of the ERCC2 gene
may be linked to endometrial cancer
2012 [Sobczuk, 2012
#1050][123]
14 XRCC1, XRCC3 XRCC1 and XRCC3 gene polymorphisms for risk of
colorectal cancer in the Chinese population.
2012 [124]
15 XRCC1 XRCC1 399Gln is an independent unfavourable
prognostic factor in unresected NSCLC treated with
radiotherapy and chemoradiotherapy
2012 [125]
16 XRCC1 XRCC1-Arg399Cln polymorphism is associated with
susceptibility to HCC, and XRCC1 Gln allele
genotype showed significant prognostic
associations.
2012 [126]
17 XRCC1 XRCC1 -77T"/>C polymorphism is associated with
cancer risk, and individuals with XRCC1-77C variant
have a significantly higher cancer risk, particularly in
the Asian population
2012 [67]
18 XRCC1 XRCC1 protein expressions in tumor is novel
candidate prognostic markers and predictive factor
for benefit from adjuvant platinum-based
chemotherapy in resectable gastric carcinoma.
2012 [75]
19 XRCC1 Genetic polymorphisms in XRCC1 gene might be
associated with overall survival and response to
platinum-based chemotherapy in lung cancer
patients.
2012 [127]
20 XRCC1 XRCC1 T-77C and eNOS G874T may confer an
increased risk of acute skin reactions to
radiotherapy in breast cancer patients
2012 [128]
21 XRCC1 XRCC1 399Gln/Gln genotype have an increased risk
of colorectal cancer
2012 [129]
22 XRCC1 XRCC1 Arg399Gln allele is a risk factor for the
development breast cancer, especially among Asian
and African populations.
2011 [130]
23 XRCC1 genetic polymorphisms in XRCC1 may affect survival
post radiotherapy for localized prostate cancer.
2010 [131]
24 XRCC1 Combined polymorphisms of ERCC1 and XRCC1
may predict OS and response to palliative
chemotherapy with FOLFOX / XELOX in metastatic
CRC patients
2010 [132]
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BER factor Key findings Year of
publication
Ref
25 XRCC1 XRCC1 194 CT genotype associated with inferior
overall survival in advanced gastric cancer patients
treated with Cisplatin-Taxane combined
chemotherapy.
2010 [133]
26 XRCC1 XRCC1 codon 194 and codon 399 polymorphisms
may predict the sensitivity of advanced NSCLC to
palliative chemotherapy treatment with vinorelbine
and Cisplatin.
2009 [134]
27 XRCC1 XRCC 1 polymorphism may predict higher response
rate to palliative Cisplatin based chemotherapy in
NSCLC patients
2009 [135]
28 XRCC1 XRCC1 polymorphism in clinical stage III may be a
prognostic survival marker in HNSCC.
2009 [136]
29 XRCC1 SNP of XRCC1 gene at codon 399 influences the
response to platinum based neo-adjuvant
chemotherapy treatment in patients with cervical
cancer.
2009 [137]
30 XRCC1, APE1 Polymorphism in APE1 and XRCC1 may represent
prognostic factors in metastatic melanoma.
2009 [138]
31 XRCC1 A rarely occurring XRCC1 variant may predict
response to Neoadjuvant chemo-radiotherapy for
the treatment of oesophageal cancer.
2009 [139]
32 XRCC1 XRCC1 variant alleles may be associated with
shorter overall survival in lung cancer patients
2008 [140]
33 XRCC1 Genotypes of XRCC1 Arginine194Tryptophan and
GGH-401Cytosine/Thymine associated with the
response to platinum based neo-adjuvant
chemotherapy treatment in patients with cervical
cancer
2008 [141]
34 XRCC1 XRCC1 variant may predict the risk of recurrence of
bladder TCC post BCG treatment.
2008 [142]
35 XRCC1 XRCC1 gene polymorphism may predict survival in
good PS advanced Gastric cancer patients treated
with Oxalipaltin based palliative chemotherapy.
2007 [143]
36 XRCC1 Polymorphism in XRCC1 gene is a potential
prognostic and predictive marker in breast cancer
patients treated with adjuvant CMF chemotherapy
2007 [144]
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BER factor Key findings Year of
publication
Ref
37 XRCC1 XRCC1 polymorphism may predict survival
advantage for SCLC and NSCLC patients after
platinum based treatment
2007 [145]
38 XRCC1 XRCC1 polymorphism may predict response to
palliative FOLFOX and can also be a prognostic
survival factor in metastatic colorectal cancer.
2006 [146]
39 XRCC1 Variant alleles of XRCC1 associated with the
absence of pathologic complete response and poor
survival in oesophageal cancer
2006 [147]
40 XRCC1 XRCC1 polpmorphism may represent a prognostic
factor in advanced NSCLC patients treated with





XRCC1 polymorphism may be a prognostic factor in
patients with CRC
2006 [95]
42 XRCC1 XRCC1-01may predict survival outcome in patients
with MBC treated with high dose chemotherapy.
2006 [74]
43 XRCC1 Combined XPD and XRCC1 genotypes might be
prognostic factors in muscle-invasive bladder cancer
patients treated with CRT.
2006 [149]
44 XRCC1 Polymorphism of XRCC1 R399Q is associated with
response to platinum-based NAC in bulky cervical
cancer
2006 [150]
45 XRCC1 Polymorphisms in the XRCC1 gene may impact the
response rate to platinum based palliative
chemotherapy in NSCLC patients.
2004 [151]
46 XRCC1 Polymorphism of XRCC1 gene may be associated
with resistance to oxaliplatin/5-FU chemotherapy in
advanced colorectal cancer.
2001 [152]
Abbreviations:ATM: ataxia telangiectasia mutated protein, FOLFOX: oxaliplatin and 5FU based chemotherapy, XELOX:
oxliplatin and Capecitabine based chemotherapy, TCC: transitional cell carcinoma, BCG: Bacillus Calmette–Guérin, CRT:
chemoradiotherapy, MBC: metastatic breast cancer.
Table 3. XRCC1
Meta-analysis of fifty three case-control studies with twenty one thousand three hundred and
forty  nine  cases  and twenty three  thousand six  hundred forty  nine controls  for  XRCC1
Arg280His polymorphism and its cancer risk were estimated using fixed or random effect
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models. Minor variant His allele and Arg-His/His-His genotypes showed a statistical associa‐
tion with the risk of cancer (OR 1.16; 95% CI 1.08-1.25) [66]. Meta-analysis of thirteen studies in‐
volving a total of eleven thousand six hundred and seventy eight individuals showed that
there was significant association between the C variant of XRCC1-77T>C polymorphism and
cancer risk in all four genetic comparison models (OR C vs. T 1.19; 95% CI 1.07-1.31; P 0.001; OR
homozygote model 1.28; 95% CI 1.07-1.52; P 0.007; OR recessive genetic model 1.22; 95% CI
1.04-1.44; P 0.015; OR dominant model 1.21; 95% CI 1.07-1.35, P 0.001). XRCC1 -77T>C polymor‐
phism is associated with cancer risk, and individuals with XRCC1 -77C variant have a signifi‐
cantly higher cancer risk, particularly in the Asian population [67]. Using a PCR-RFLP method,
XRCC1 Arg194Trp, Arg280His and Arg399Gln were genotyped in six hundred and twenty
four glioma patients and five hundred and eighty healthy controls. Significant differences in
the distribution of the Arg399Gln allele were detected between glioma patients and healthy
controls by a logistic regression analysis (OR 1.35; 95% CI 1.17-1.68; P 0.001). Arg399Gln var‐
iant (allele A) carriers had an increased glioma risk compared to the wild-type (allele G) homo‐
zygous carriers (OR 1.40, 95%CI 1.12-1.76, P 0.003)[68]. In a prospective follow-up study, a
cohort of three hundred and ten ovarian cancer patients treated with platinum-based chemo‐
therapy between January 2005 to January 2007 were followed up to 2010. Genotyping of
XRCC1 and XRCC3 polymorphisms was conducted by TaqMan Gene Expression assays. Low‐
er survival rate in XRCC1 399 Arg/Arg genotype than in Gln/ Gln, with a significant increased
risk of death (HR 1.69; 95% CI 1.07-2.78) were observed. However no significant association be‐
tween XRCC1 Arg194Trp and XRCC1 Arg280His gene polymorphisms and ovarian cancer
death was observed. [69]. A multicenter 1:1 matched case- control study of three hundred and
seven pairs of gastric cancers patients and controls between October 2010 and August 2011 was
undertaken. XRCC1 Arg194Trp and ADPRT Val762Ala were sequenced. Demographic data
collected using a self-designed questionnaire. Individuals carrying XRCC1 Trp/Trp or Arg/Trp
variant  genotype had a  significantly  increased risk of  gastric  cancer  (OR 1.718;  95% CI,
1.190-2.479). [70]. In a cohort of advanced NSCLC patients treated with platinum based chemo‐
therapy,  XRCC1  polymorphism  was  evaluated.  XRCC1  Arg194Arg,  FAS-1377GG,  and
FASL-844T allele displayed no response to platinum, whereas patients with XRCC1 194Trp al‐
lele and XPC PAT +/+ had 68.8% response rate to platinum. In Logistic Regression analysis, a
significant gene-dosage effect was detected along with the increasing number of favourable
genotypes of these four polymorphisms (P 0.00002). Multi-loci analysis showed the impor‐
tance of genetic variations involved in BER repair and apoptotic pathways in sensitivity of plat‐
inum-based chemotherapy in NSCLC [71]. In a meta-analysis of forty four published case-
control studies demonstrated that codon 194, codon 399 and -77 T > C polymorphisms of
XRCC1 gene might have contributed to individual susceptibility to lung cancer [72]. In a anoth‐
er study, sixty two advanced NSCLC patients in a training set and forty five patients in a vali‐
dation set treated with gemcitabine/platinum were genotyped for XRCC1 polymorphism.
Wild-type genotype of XRCC1 Arg399Gln (G/G) was associated with decreased median over‐
all survival than those carrying variant genotypes (G/A+A/A). In addition, there was a statisti‐
cally significant longer median OS in patients carrying wild-type ERCC2 Asp312Asn genotype
(G/G) (51 months, 95% CI, 19-82 months versus 10 months, log-rank test, P < 0.001) than those
carrying heterozygous variant genotypes (G/A). This points out the predictive biomarker sta‐
tus of XRCC1 in platinum treated NSCLC patients[73]. XRCC1 polymorphism is a potential
predictive marker of platinum based treatment response in non-small cell lung carcinoma, col‐
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orectal carcinoma, advanced gastric, advanced cervical, advanced operable oesophageal can‐
cer. It may also predict response to adjuvant CMF chemotherapy and high dose chemotherapy
in breast cancer [74].
In a training and validating cohort of Gastric cancer patients, XRCC1 protein levels were signif‐
icantly downregulated in gastric cancers compared to adjacent non-cancerous tissues. Low tu‐
mour XRCC1 expression significantly correlated with shorter overall survival as well as with
clinic-pathologic characteristics in patients without adjuvant treatment. Multivariate regres‐
sion analysis showed that low XRCC1 expressions, separately and together, were independent
negative markers of OS. Adjuvant fluorouracil-leucovorin-oxaliplatin (FLO) significantly im‐
proved OS compared with surgery alone (log-rank test, P 0.01). However, this effect was evi‐
dent only in the XRCC1 low expression group (HR 0.44, 95% CI 0.26-0.75; P 0.002); Adjuvant
fluorouracil-leucovorin-platinum (FLP) did not improve OS, except in the patients with low
XRCC1 expressions (P 0.024). XRCC1 protein expressions in tumour are novel candidate prog‐
nostic markers and predictive factors for benefit from adjuvant platinum-based chemotherapy
(FLO or FLP) in patients with resectable gastric carcinoma [75]. SMUG1, FEN1, XRCC1 and
ATM are involved in ROS induced oxidative DNA damage repair in gastric cancer patients.
High expression of SMUG1, FEN1 and XRCC1 correlated to high T-stage (T3/T4) (P 0.001, 0.005
& 0.02 respectively). High expression of XRCC1 and FEN1 also correlated to lymph node posi‐
tive disease (P 0.009 and 0.02 respectively). High expression of XRCC1, FEN1 & SMUG1 corre‐
lated with poor disease specific survival (P 0.001, 0.006 and 0.05 respectively) and poor disease
free survival (P 0.001, 0.001 & 0.02 respectively) [76]. Muscle-invasive transitional cell carcino‐
ma tumour samples from ninety patients treated with radical radiotherapy was evaluated for
XRCC1 protein expression. Nuclear staining of XRCC1 was 96.5% (range, 0.6-99.6%). High ex‐
pression levels of XRCC1 (> or = 95% positivity) were associated with improved patient cancer-
specific survival (log-rank, P 0.006) [77].
XRCC1 has shown to be a promising prognostic biomarker in a majority of cancer groups
including HNSCC, breast, ovarian, endometrial, cervical, lung, gastric, oesophageal, pancre‐
atic, glial, colorectal, hepatocellular, bladder transitional cell carcinoma, metastatic melanoma
and non melanomatous skin cancer.
2.4. FEN1
FEN1 is a structure-specific 5′ endo/exonuclease with a range of functions during DNA repair
and replication. It is a BER long patch protein. FEN1 also has a role in the processing of the
okazaki lagging DNA strand synthesis. As an endonuclease, FEN1 recognizes double-stranded
DNA with a 5′-unannealed flap and makes an endonucleolytic cleavage at the base of the flap.
As a 5′ exonuclease, it degrades nucleotides from a nick or a gap. It may also be involved in
maintaining stability of telomeres, inhibiting repeat sequence expansion and involved in
creation of double-stranded DNA breaks when mammalian cells are subjected to X-ray
irradiation[78]. Human flap endonuclease 1 gene has been shown to have 4 somatic mutations,
one polymorphism, and two transcripts in the Ensembl data base. In the following section we
will review the potential of FEN1 as a prognostic, predictive biomarker and its feasibility as a
drug target in cancer treatment (See Table 4).
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BER factor Key findings Year of
publication
Ref
1 FEN1 Polymorphisms in FEN1 confer susceptibility to gastrointestinal
cancers
2012 [79]
2 FEN1 High expression of XRCC1, FEN1 & SMUG1 correlated with poor
disease free survival
2012 [76]
3 FEN1 FEN1 protein expression was also associated with poor prognosis
in prostatectomy-treated patients. Knock-down of FEN1 with
small interfering RNA inhibited the growth of LNCaP cells.
2012 [83]
4 FEN1 Genetic polymorphisms in FEN1 confer susceptibility to lung
cancer.
2009 [153]
5 FEN1 FEN1 overexpression is common in testis, lung and brain tumors.
Down-regulation of FEN1 by siRNA increased sensitivity to
methylating agents (temozolomide, MMS) and cisplatin in LN308
glioma cells
2009 [81]
6 FEN1 RAD54B-deficient human colorectal cancer cells are sensitive to SL
killing by reduced FEN1 expression
2009 [85]
7 FEN1 FEN1 is significantly up-regulated in multiple cancers. The
overexpression and promoter hypomethylation of FEN1 may serve
as biomarkers for monitoring the progression of cancers
2008 [82]
8 FEN1 FEN-1 is overexpressed in prostate cancer and is associated with
higher Gleason score.
2006 [84]
Abbreviations: SMUG1: Single-strand selective monofunctional uracil-DNA glycosylase
Table 4. FEN1
Human germ line variants (-69G >A and 4150G > T) in the FEN1 gene have been associated
with DNA damage in coke oven workers and lung cancer risk in general populations. This
was studied in one thousand eight hundred and fifty gastrointestinal cancer (hepatocellular
carcinoma, esophageal cancer, gastric cancer and colorectal cancer) patients and two thousand
two hundred and twenty two healthy controls. It was found that the FEN1 -69GG genotypes
were significantly correlated to increased risk for developing gastrointestinal cancer compared
with the -69AA genotype highlighting FEN1 as an important gene in human gastrointestinal
oncogenesis and a potential biomarker [79]. We recently investigated this relationship in a
cohort of gastric cancer patients and found high expression of FEN1 correlated to lymph node
positive disease with poor disease specific survival and poor disease free survival [76]. In pro-
myelocytic leukemia cell line HL-60, gene expression of FEN-1 has been shown to be higher
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in cells during mitotic phase as compared to cells in the resting phase. FEN1 expression
markedly decreases when these cells reach maturity upon induction of terminal differentiation
[80]. This study pointed out the relationship between increased FEN1 expression and prolif‐
erating cancer cells. Subsequent studies showed increased FEN 1 expression in testis, lung and
brain cancer specimens as studied by Western blot analysis and compared with the normal
tissue from the same patient. FEN1 over expression was observed in nineteen samples from
testicular tumours (mostly seminomas), four samples from NSCLC, nine samples from
glioblastoma multiforme and in five samples from astrocytomas. Down regulation of FEN1
expression in LN308 glioblastoma cell line by siRNA resulted in hypersensitivity to cisplatin,
temozolomide, nimustine and methyl methanesulfonate (MMS)[81]. Statistically significant
increased amount of FEN1 expression has been demonstrated in breast tumor tissue (~2.4 fold,
P< 0.0001, n = 50), uterine tumor tissue (~2.3 fold, P = 0.0006, n = 42), colon tumor tissue (~1.5
fold, P < 0.0001, n = 35), stomach tumor tissue (~1.5 fold, P= 0.0005, n = 28), lung tumor tissue
(~1.9 fold, P = 0.0066, n=21) and kidney tumor tissue (~2.3 fold, P = 0.0063, n = 20), compared
to matched normal tissues[82]. FEN1 also found to be increased in castration refractory
prostate cancer (CRPC) cells. The knock-down of FEN1 with si RNA inhibited the growth of
these LNCaP cells [83] pointing it as a potential drug target in prostate cancer. In primary
prostate cancer from two hundred and forty six patients who had had a radical prostatectomy,
FEN-1 nuclear expression correlated with Gleason score. These results suggest that FEN-1
might be a potential marker for selecting patients at high risk and therapy [84]. Interestingly,
synthetic lethality (SL) has been observed in RAD54B-deficient human colorectal cancer cell
line by iatrogenic reduction of FEN1 expression thus demonstrating it to be a potential novel
therapeutic biological target [85].
2.5. Polymerase beta, PCNA
Polymerase beta (pol β) is essential for short patch BER. It is present in all tissues at a lower
level [86] and has no cell-cycle dependence. Majority of BER proceeds through the short-patch
whereby a single nucleotide is removed and replaced. Unlike other DNA polymerases, pol β
has no proof reading capability[87] hence its over expression has the potential for mutagene‐
sis[88, 89]. Proliferating cell nuclear antigen( PCNA) is an accessory protein required for
replication by DNA polymerase δ, and as a consequence, PCNA is required during the long
patch BER [90]. Lesions left unrepaired by the short patch BER is facilitated by PCNA to switch
to the long patch BER. PCNA then helps polymerase δ to excise and replace 2-8 nucleotide
patch in the long path of BER. Table 5 summarizes recent insight into the prognostic and
predictive significance of pol β and PCNA.
Twenty somatic pol β mutations in prostate tumors are already known. The somatic missense
pol β mutations (p.K27N, p.E123K, p.E232K, p.P242R, p.E216K, p.M236L, and the triple mutant
p.P261L/T292A/I298T) were assessed in vitro for the biochemical properties of the polymerase.
Experiments suggest that interfering with normal polymerase beta function may be a frequent
mechanism of prostate tumour progression [91].Three non-synonymous single nucleotide
substitutions, Gln8Arg, Arg137Gln and Pro242Arg have been identified as polymorphisms in
DNA Pol β. The Arg137Gln variant demonstrates significantly reduced polymerase activity
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and impaired interaction with PCNA, and reduced BER efficiency when assayed in a recon‐
stitution assay or with cellular extracts. Other polymorphisms within DNA Pol β include
A165G and T2133C, which were associated with overall survival in a study of patients with
pancreatic cancer [92, 93]. One hundred and fifty two ovarian cancer samples subjected to RT-
PCR and sequencing, a variant of polymerase beta (deletion of exon 4-6 and 11-13, comprising
of amino acid 63-123, and 208- 304) was detected in heterozygous condition. Statistical analysis
showed this variant to be associated with risk of stage IV, endometrioid type ovarian carci‐
noma[94]. In a case-control study (three hundred and seventy seven cases along with three
hundred and twenty nine controls) designed to assess gene-environment interactions, samples
were genotyped by use of an oligonucleotide microarray and the arrayed primer extension
technique. Twenty-eight single nucleotide polymorphisms in 15 DNA repair genes including
pol β P242R were evaluated. It was demonstrated that pol β polymorphism is associated with
a decreased risk of colorectal cancer [95]. Pol β over expression reduces the efficacy of
anticancer drug therapies including ionizing radiation, bleomycin, monofunctional alkylating
agents and cisplatin. Small-scale studies in different cancers showed that pol β is mutated in
approximately 30% of tumours. These mutations further lower pol β fidelity in DNA synthesis
exposing the genome to serious mutations. These findings suggested pol β to be a promising
therapeutic target in cancer treatment [96].
BER factor Key findings Year of
publication
Ref
1 Pol beta variant form of Pol β cDNA is associated with edometrioid
type, stage IV ovarian carcinoma
2012 [94]
2 Pol beta A proportion of prostate cancer patients express
functionally important somatic mutations of pol β.
2011 [91]
3 Pol Beta Over expression of pol β reduces the efficacy of anticancer
drug therapies including, Cisplatin, bleomycin,
monofunctional alkylating agents and ionizing radiation.
2011 [96]
4 Pol beta, PCNA More than 30% of human tumors characterized to date
express DNA pol β variants, a polymorphism encoding an
arginine to glutamine substitution, R137Q, has lower
polymerase activity
2009 [92]
4 Pol beta, PCNA Pancreatic cancer patients carrying at least 1 of the 2
homozygous variant pol β GG or CC genotypes have a





pol β P242R was also associated with decreased risk of
colorectal cancer
2006 [95]
Table 5. Other BER factors
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3. Summary and the future developments
Numerous DNA base excision repair proteins are currently under development as potential
biomarkers and therapeutic targets. Studies presented above provide compelling evidence that
BER factors are promising prognostic and predictive biomarkers in cancer. More recent
evidence also suggests that BER is an attractive target for drug discovery. APE1 inhibitors, for
example, are currently in development and may have therapeutic application in the near
future. [34, 97, 98]. Moreover, DNA polymerase beta inhibitor is also currently under devel‐
opmental stage and early reports reveal the ability of DNA pol β inhibitors to potentiate the
cytotoxicity of alkylating agents [99]. In contrast, several other studies demonstrate that pol
β-null cells, although sensitive to temozolomide, are not sensitive to other chemotherapeutic
agents such as melphalan, mitozolomide, BCNU, and IR [34, 100, 101]. Therefore further
research is warranted to confirm pol β as a drug target in cancer.The principles of synthetic
lethality has been transferred from the bench to the bedside with PARP-1 inhibitors in BRCA-
deficient (HR-defective) cancer cells [102, 103]. Recent evidence suggests that other factors in
BER are also important synthetic lethality targets for personalized cancer therapy.
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